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Summary
Antibiotics are powerful therapeutics but are not equally
effective against all cells in bacterial populations. Bacteria
that express an antibiotic-tolerant phenotype (‘‘persisters’’)
can evade treatment [1]. Persisters can cause relapses of
the infection after the end of the therapy [2]. It is still poorly
understood whether persistence affects the evolution of
bacterial virulence. During infections, persisters have been
found preferentially at particular sites within the host [3, 4].
If bacterial virulence factors are required to reach such sites,
treatment with antibiotics could impose selection on the
expression of virulence genes, in addition to their well-es-
tablished effects on bacterial resistance. Here, we report
that treatment with antibiotics selects for virulence and fos-
ters transmissibility of Salmonella Typhimurium. In a mouse
model for Salmonella diarrhea, treatment with the broad-
spectrum antibiotic ciprofloxacin reverses the outcome of
competition between wild-type bacteria and avirulent mu-
tants that can spontaneously arise during within-host evolu-
tion [5]. While avirulent mutants take over the gut lumen and
abolish disease transmission in untreated mice, ciprofloxa-
cin tilts the balance in favor of virulent, wild-type bacteria.
This is explained by the need for virulence factors to invade
gut tissues and form a persistent reservoir. Avirulent mu-
tants remain in the gut lumen and are eradicated. Upon
cessation of antibiotic treatment, tissue-lodged wild-type
pathogens reseed the gut lumen and thereby facilitate dis-
ease transmissibility to new hosts. Our results suggest a
general principle by which antibiotic treatment can promote
cooperative virulence duringwithin-host evolution, increase
duration of transmissibility, and thereby enhance the spread
of an infectious disease.Results and Discussion
The progression of an infectious disease and transmission to
new hosts can be altered by evolutionary changes in the path-
ogen population during the course of a single infection [6, 7].
Although such within-host evolution can affect a range of
different biological traits, changes in the pathogen’s virulence
are particularly significant since they determine damage done
to the current host as well as disease transmission [8]. How*Correspondence: mederic.diard@micro.biol.ethz.ch (M.D.), martin.
ackermann@env.ethz.ch (M.A.), hardt@micro.biol.ethz.ch (W.-D.H.)virulence evolves during within-host competition depends on
costs versus benefits of virulence for the individual pathogen.
Situations in which virulence traits are costly to express for
the individual pathogen cell, but elicit a benefit for the group
of pathogens in a host, are known as ‘‘cooperative virulence.’’
In such cases, within-host evolution tends to reduce virulence
by allowing the rise of ‘‘defectors,’’ which are avirulent mu-
tants that benefit from the expression of virulence traits by
other members of the population without contributing to it
themselves [5, 7, 9–11]. Identifying the factors that determine
within-host evolution of virulence is crucial for under-
standing and eventually controlling disease progression and
transmission.
Here, we used an experimental host-pathogen system to
test whether antibiotics can promote cooperative virulence
and disease transmission. We worked with a mouse model
for infections with the diarrheal pathogen Salmonella enterica
subspecies 1 serovar Typhimurium (S. Typhimurium) strain
SL1344, which is highly sensitive to ciprofloxacin (MIC =
0.015 mg/ml; Figure S1 available online; [12]). In this system,
expression of the pathogen’s Type Three Secretion System 1
(ttss-1) is a cooperative trait that triggers gut tissue invasion
and thereby elicits gut inflammation [5, 13]. The inflammation
allowsS. Typhimurium to outcompete the intestinal microbiota
in the gut lumen [14], a benefit that is accessible to all luminal
S. Typhimurium cells, irrespective of whether they express
ttss-1 or not. Importantly, the expression of ttss-1 imposes a
substantial growth defect [5, 15]. Consequently, genetically
avirulent mutants (defectors) that never express ttss-1 but
benefit from the inflammation induced by others can outgrow
the wild-type ‘‘cooperators’’ in the gut lumen [5]. These defec-
tors carrymutations in hilD and lack a central positive regulator
of ttss-1 expression [16]. On the other hand, defectors are
incapable of invading into the gut tissue [13, 17, 18]. The intra-
cellular milieu that wild-type S. Typhimurium is facing in the
gut tissue can induce a phenotype of slow growth and antibi-
otic tolerance (persistence) [3, 4]. This suggests that virulent
wild-type bacteria, but not the avirulent defectors, can reach
the host tissue that can confer protection from antibiotics
treatment. Based on these observations, we hypothesized
that antibiotic treatment might favor survival of virulent wild-
type S. Typhimurium and thereby select for cooperative
virulence.
The Rise of Avirulent Defectors Reduces Disease
Transmissibility
We first verified that, in the absence of antibiotics treatment,
avirulent defectors become dominant in the gut lumen
and established that this interrupts disease transmission to
new hosts. Here, we used 129SvEv mice, because these
Nramp+/+ animals are known to survive long-term infection
with wild-type S. Typhimurium [14, 19]. Mice were inoculated
withmixtures of 99%wild-type S. Typhimurium and 1%defec-
tors, and fecal samples were taken to estimate population
sizes of the two types in the gut lumen and to assess the po-
tential of fecal-oral disease transmission. The proportion of
defectors rose to 10%by day 2 postinfection (p.i.) and to about
99% by day 10 p.i. (Figure 1A), in line with our previously
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Figure 1. Avirulent Defectors Outcompete Viru-
lent Wild-Type Cooperators in the Gut Lumen
and Reduce Disease Transmissibility
(A and B) 129SvEv mice were infected with a
100:1 mixture of wild-type cooperators (M3067,
red symbols) and hilD defectors (M3105, blue
symbols; 5 3 107 cfu total, by gavage).
(A) Absolute population sizes in the inoculum and
the feces as determined by plating.
(B) Population sizes of the tissue-lodged bacteria
at day 10 postinfection as determined by a genta-
mycin protection assay, indicating that coopera-
tors are predominant in this compartment.
(C and D) Transmissibility experiments. C57BL/6
mice were inoculated with a fecal suspension
from donor mice at day 10 p.i. (approx. 5 3 107
cfu total). Infections with the original wild-type
or hilD strains (5 3 107 cfu by gavage) served as
controls.
(C) Fecal population sizes in control mice inocu-
lated with the parental wild-type or hilD strains
(open circles), donor mice (filled circles), and
recipient mice (triangles).
(D) Intestinal inflammation at day 1 p.i. deter-
mined by pathology scoring on stained cecal
cross-sections. Dashed line delimits the thres-
hold between healthy and inflamed tissues.
(A–C) Dashed lines mark limits of detection.
(D) n.s., statistically nonsignificant (p R 0.05),
***p < 0.001, Mann-Whitney U test.
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2001published results [5]. Controlled transmission was performed
into C57BL/6 mice (Nramp2/2; very well established infection
kinetics [12]) to directly quantify the transmission potential of
the infection at the end of the experiment. Fecal pellets from
donor mice at day 10 p.i. were homogenized and used to orally
infect recipient mice. The S. Typhimurium population that
arose in the recipient mice was dominated by defectors, and,
consequently, no inflammation was observed (Figures 1C
and 1D). This was equivalent to control infections with the
original hilDmutant strain alone. In contrast, control infections
with the original wild-type strain lead to pronounced disease.
These results established that the rise of avirulent defectors
in the gut lumen of infected mice indeed impedes disease
transmissibility, at least in the context of our coinoculation
experiments.
Although avirulent defectors became dominant in the gut
lumen, the population dynamics in the gut tissue were
different: defectors remained underrepresented by day 10
p.i. compared to wild-type cooperators. This observation
was based on plating of gut-tissue-lodged bacteria from
mice infected with mixtures of cooperators and defectors
(Figure 1B) and supported by a fluorescence microscopy
approach in mice infected either by the wild-type or the
defector strains alone (Figures 2A and 2B). When S. Typhimu-
rium enters host cells, it expresses the needle component
gene ssaG [20], and we therefore used a plasmid carrying
gfp-mut2 fused to the ssaG promoter to enumerate S. Typhi-
murium loads in the gut tissue [17]. The fluorescence mi-
croscopy-based enumeration of tissue loads was furtherconfirmed by antibody staining of tis-
sue-lodged bacterial cells [21]. With
this technique we detected numerous
cooperators but very few defectors in
the gut tissue (Figures 2A and 2B). This
finding correlates with tissue plating,which showed that wild-type cooperators infected the gut tis-
sue much more efficiently than the defectors (Figure 2C) while
the luminal population sizes were equivalent (Figure 2D). This
indicates that wild-type S. Typhimurium but not defectors
enter the gut tissue, a site that has previously been reported
to confer protection from antibiotics [3, 4]. These results es-
tablished the basic premise of our hypothesis: cooperators
and defectors dominate in different host compartments and
could thus be differentially sensitive to antibiotics whose effi-
cacy differs between compartments.
Ciprofloxacin Promotes Virulence and Disease
Transmission
We then tested the prediction that antibiotic treatment can tilt
the selective balance between cooperators and defectors
and promote cooperative virulence. All strains used in this
study showed comparable sensitivity to ciprofloxacin and
identical minimal inhibitory concentrations (MIC = 0.015 mg/
ml) (Figure S1; Supplemental Information). We coinfected
mice with wild-type S. Typhimurium and the hilD mutant as
described above and treated with two successive doses of
ciprofloxacin (3 mg per os each in an interval of 8 hr) at day
2 p.i. This was sufficient to eliminate both S. Typhimurium
strains from the gut lumen by day 3 p.i. (Figure 3A). In
contrast, S. Typhimurium was still detectable in the gut tis-
sue. Differential plating revealed that all bacteria in the gut
tissue were from the wild-type strain, and no defectors
were found (Figure 3B). In line with previous work, fecal shed-
ding of S. Typhimurium relapsed a few days after we ended
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Figure 2. Defector Mutants Cannot Efficiently
Invade the Gut Tissue
129SvEv mice were infected for 1 day with gfp-
labeled bacteria (wild-type or hilD, pM975; 5 3
107 cfu by gavage), and bacterial loads in the
gut tissue were analyzed by fluorescence micro-
scopy and by plating.
(A) Representative fluorescence microscopy im-
ages. Tissue sections were stained for ICAM-1/
CD54 (Cy3-IgG) and F-actin (Alexa 647-Phalloi-
din). Inserts, green fluorescent signal from bacte-
ria lodged in the tissue. Lu., Lumen; S.M.,
Submucosa. Scale bars represent 50 mm.
(B) Enumeration of the intracellular bacteria per
tissue section.
(C) Plating assay quantifying the tissue-lodged S.
Typhimurium population.
(D) Salmonella population sizes in feces at day 1
p.i. The two strains colonized the cecum lumen at
equivalent levels (n.s., statistically nonsignifi-
cant, Mann-Whitney U test p R 0.05) whereas
the wild-type was more efficient at invading the
tissues. The samples were from the same mice
as analyzed in (A) and (B). **p < 0.01, Mann-Whit-
ney U test.
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2002the antibiotic treatment [3, 22]. At day 10 p.i., the relapsing S.
Typhimurium populations had reached the loads prior treat-
ment in feces and cecal tissues. Strikingly, the stool and tis-
sue populations were exclusively composed of the virulent
wild-type cooperators, and defectors were not detected (Fig-
ures 3A and 3B). Comparable observations were made when
mice were infected with 100% wild-type cooperators and
defectors naturally arose by mutation (Figure S2). Control ex-
periments verified that the dominance of the virulent wild-
type S. Typhimurium after treatment was not a consequence
of beneficial mutations acquired during infection; clones
isolated from infected mice were indistinguishable from a
naive wild-type strain in terms of competitive ability in the
host (Figure S3) and sensitivity to ciprofloxacin (MIC =
0.015 mg/ml). Also, dominance of the virulent wild-type coop-
erators after treatment was not attributable to numerical dif-
ferences between wild-type and defectors in the gut lumen
before treatment or to the markers used to distinguish be-
tween the strains (Figure S4). These results supported the
interpretation that bacteria causing the relapse originated
from a phenotypically persistent reservoir in the host’s tissue,
not from a pool of genetically resistant pathogenic cells.
Since we had found that the rise of defectors abolishes dis-
ease transmission, one would expect that the selective sup-
pression of defectors through antibiotics would reverse this
effect. We performed transmission experiments to investigate
whether the gut luminal S. Typhimurium population formed
during the relapse is capable of eliciting disease in recipient
hosts (Figures 3C and 3D). In line with our hypothesis,
controlled transmissions from ‘‘relapsing’’ donor mice (at
day 10, i.e., 7 days after the last ciprofloxacin dose) led topronounced mucosal inflammation in
the recipient animals. The level of
inflammation was indistinguishable
from inflammation in control mice in-
fected with the original wild-type S. Ty-
phimurium strain (Figures 3C and 3D)
and much stronger than the disease
elicited by controlled transmissionwithout ciprofloxacin treatment (compare Figures 3D and
1D). Thus, antibiotic treatment can indeed enhance disease
transmissibility.
Finally, we tested whether invasion of the gut tissue in itself
was necessary for S. Typhimurium to survive antibiotics treat-
ment. Avirulent defectors that spontaneously arise in infected
mice [5] and that we used here may differ from the wild-type
in other traits besides the impaired ttss-1 expression. This
is because HilD regulates the expression of several other
genes [23–25]. Formally, we could not exclude that these
effects contributed to the differential sensitivity to antibiotics,
e.g., by slowing down the bacterial growth rate of the ttss-1-
expressing fraction of some gut luminal S. Typhimurium
population. In fact, in vitro, such a reduced growth rate of
the ttss-1-expressing cells can confer ciprofloxacin persis-
tence in nonhost environments [26]. This raised the question
whether tissue invasion per se was the decisive factor in our
in vivo experiments. To specifically evaluate the role of tissue
entry in the survival of antibiotic treatment, we used a mutant
of S. Typhimurium (D4) carrying an intact hilD gene but deleted
for the four TTSS-1 effectors that drive gut tissue invasion
(i.e., sopE, sopE2, sipA, and sopB [18, 27]). We mixed this
mutant with the wild-type and inoculatedmice with a 1:10 ratio
ofD4 versus wild-type S. Typhimurium. This ratio was stable in
the feces during the first 2 days of the experiment (Figures 4A
and S2A), which showed that the two strains were equally
competitive in the gut lumen and that the D4 mutant was still
featuring the growth defect associated with ttss-1 expression.
Importantly, D4 mutants did not efficiently enter the gut tis-
sue (Figures 4B, 4C, and S2B). As before, ciprofloxacin treat-
ment eliminated all bacteria (D4 and wild-type S. Typhimurium
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Figure 3. Ciprofloxacin Treatment Selects for
Virulent Wild-Type Cooperators and Favors
Disease Transmissibility
129SvEv mice were infected with a 100:1 mixture
of wild-type cooperators (M3067, red symbols)
and hilD defectors (M3105, blue symbols; 5 3
107 cfu total, by gavage). Two doses of ciproflox-
acin were applied at 48 and 56 hr p.i.
(A) Absolute population sizes in the inoculum and
the feces were determined by plating. At day 10
p.i., feces harbored only wild-type cooperators.
(B) Population sizes of the tissue-lodged bacteria
as determined by plating of washed cecum tis-
sue samples. Cooperators are predominant in
this compartment. No defectors were detectable
after ciprofloxacin treatment.
(C and D) Transmissibility experiments. C57BL/6
mice were inoculated with a fecal suspension
from ciprofloxacin-treated donor mice (approx.
5 3 107 cfu total, day 10 p.i.). Infections with the
original wild-type or hilD strains (5 3 107 cfu by
gavage) served as controls.
(C) Fecal population sizes in control mice inocu-
lated with the parental wild-type or hilD strains
(open circles), donor mice (filled circles), and
recipient mice (triangles).
(D) Intestinal inflammation at day 1 p.i. deter-
mined by pathological scoring on stained cecal
cross-sections.
Dashed line delimits the detection limit or the
threshold between healthy and inflamed
tissues; n.s., statistically nonsignificant (p R
0.05), *p < 0.05, ***p < 0.001, Mann-Whitney U
test. A red line and arrow mark the time of cipro-
floxacin treatment.
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2003alike) from the gut lumen, and relapse occurred after the end
of the treatment. The relapsing population was composed
almost exclusively of wild-type S. Typhimurium (Figure 4A,
day 10 p.i.). This supported the notion that the different
spatial localization of wild-type S. Typhimurium and avirulent
mutants in the host was responsible for the differential
sensitivity to antibiotics. This would be in line with recent
work showing that the growth of intracellular S. Typhimurium
is slowed down (e.g., by toxin-antitoxin activity), thus
representing a type of ‘‘host-cell-induced’’ persistence [3, 4].
However, we cannot formally rule out that limited tissue
penetration of the antibiotic may also contribute to some
extent to the selective advantage of tissue-lodged wild-type
S. Typhimurium.Conclusions
Reduced growth rates have emerged as a cardinal feature
conferring bacterial persistence [1]. In the case of S. Typhimu-
rium, such slow growth can be observed outside of host
tissues (i.e., as a consequence of ttss-1 expression in vitro
[15, 26]) or within host tissues, presumably through host-cell-
induced mechanisms [3, 4, 28]. Our experiments show that
the latter can have important consequences for within-host
evolution of virulence and disease transmissibility. During
antibiotic treatment, tissue-lodged virulent clones of S. Typhi-
murium but not gut luminal avirulent defectors do form a
persistent reservoir. After cessation of therapy, virulent per-
sisters reseed the gut from the host tissues and are transmis-
sible to new hosts. This provides essential new information
on selective effects of antibiotics. Although there is a strongfocus on antibiotics-driven selection for resistance, our results
establish that treatment can also impact within-host evolution
of virulence and promote disease transmission. Understand-
ing such unexpected effects of antibiotics and the evolutionary
consequences of persister formation is important for devising
improved antibacterial strategies.
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Figure 4. Tissue Entry Is Necessary to Form a Ciprofloxacin-Persistent S.
Typhimurium Reservoir
(A and B) 129SvEv mice were infected with a 10:1 mixture of wild-type S.
Typhimurium (SB300, red) and the attenuated mutant (M3143; D4, green).
Two doses of ciprofloxacin were applied at 48 and 56 hr p.i.
(A) Absolute population sizes in the feces as determined by plating.
(B) Gut tissue loads as analyzed by plating. Dashed lines mark limits of
detection. *p < 0.05, **p < 0.01; Mann-Whitney U test. A red line and arrow
mark the time of ciprofloxacin treatment. The effector-deficient strain D4
can colonize the gut lumen, but fails to colonize the gut tissue.
(C and D) Infections in 129SvEv mice with one strain, alone. The mice were
infected with M3143 (D4, green; 5 3 107 cfu by gavage) and the population
sizes were determined in tissues (C) and feces (D) at day 1 p.i. Data from
mice infected with wild-type S. Typhimurium (M3067, red, Figure 2) are
shown for comparison. *p < 0.05, **p < 0.01, Mann-Whitney U test.
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